Arun Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Arun Kumar has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Asmita Deka Dey
Chitkara College of Pharmacy, Chitkara University, Punjab, India
7 shared publicationsTapan Behl
Chitkara College of Pharmacy, Chitkara University, Punjab, India
7 shared publications- Tapan Behl
Amity School of Pharmaceutical Sciences, Amity University, Mohali, Punjab, India
5 shared publications - Gokhan Zengin
Department of Biology Science Faculty Selcuk University Konya Turkiye
4 shared publications - Simona Bungau
Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania
4 shared publications Swati Chadha
Chitkara College of Pharmacy, Chitkara University, Punjab, India
4 shared publications
Latest Publications
- 31 March 2026
- Published by Elsevier in Materials Today Chemistry
- Vol. 53
Advances in hyaluronic acid-based biomaterials: From chemistry and synthesis to biomedical implementation
- 31 March 2026
- Published by Elsevier in Materials Today Chemistry
- Vol. 53
Advances in hyaluronic acid-based biomaterials: From chemistry and synthesis to biomedical implementation
- Open Access
- 1 February 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-40
Biomimetic Nanoparticles for Targeted and Efficient Cancer Therapy: Progress, Challenges and Perspectives
Cancer remains a prominent cause of global mortality, with over 200 identified forms, and is projected to have a 25% increase in fatalities by 2030. Early diagnosis and treatment are crucial, but current therapy, which includes surgery, chemotherapy, immunotherapy, hormonal therapy, targeted therapy, and radiotherapy, faces challenges such as non-targeted drug distribution, toxicity, and limited efficacy. In recent years, biomimetic nanoparticles have emerged as a promising nanocarrier with great potential that enables site-specific drug release, improves biocompatibility, prolongs circulation time, and minimizes immune responses. Among various biomimetic nanoparticles, nanoparticles coated with cell membranes, such as those from cancer cells, immune cells, and stem cells, have been shown to have great potential for cancer treatment. The cell membrane-coated nanoparticles, further functionalized with tumor-specific ligands, demonstrated potential in improving half-life, drug specificity, and overall therapeutic efficacy. In this comprehensive article, we have reviewed recent advances in cell membrane-coated biomimetic nanoparticle systems for cancer therapy. We discussed the biomimetic nanoparticles coated with membranes of red blood cells, cancer cells, platelet cells, macrophages, exosomes, hybrid cells, and protein/serum albumin for cancer therapy. This review also highlights challenges associated with large-scale production, maintaining structural integrity during drug loading, clinical and biosafety aspects, regulatory requirements, and the clinical translation of the cell membrane-coated biomimetic nanoparticle systems.
- 1 February 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-40
Open AccessBiomimetic Nanoparticles for Targeted and Efficient Cancer Therapy: Progress, Challenges and Perspectives
Cancer remains a prominent cause of global mortality, with over 200 identified forms, and is projected to have a 25% increase in fatalities by 2030. Early diagnosis and treatment are crucial, but current therapy, which includes surgery, chemotherapy, immunotherapy, hormonal therapy, targeted therapy, and radiotherapy, faces challenges such as non-targeted drug distribution, toxicity, and limited efficacy. In recent years, biomimetic nanoparticles have emerged as a promising nanocarrier with great potential that enables site-specific drug release, improves biocompatibility, prolongs circulation time, and minimizes immune responses. Among various biomimetic nanoparticles, nanoparticles coated with cell membranes, such as those from cancer cells, immune cells, and stem cells, have been shown to have great potential for cancer treatment. The cell membrane-coated nanoparticles, further functionalized with tumor-specific ligands, demonstrated potential in improving half-life, drug specificity, and overall therapeutic efficacy. In this comprehensive article, we have reviewed recent advances in cell membrane-coated biomimetic nanoparticle systems for cancer therapy. We discussed the biomimetic nanoparticles coated with membranes of red blood cells, cancer cells, platelet cells, macrophages, exosomes, hybrid cells, and protein/serum albumin for cancer therapy. This review also highlights challenges associated with large-scale production, maintaining structural integrity during drug loading, clinical and biosafety aspects, regulatory requirements, and the clinical translation of the cell membrane-coated biomimetic nanoparticle systems.
- 20 June 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 681, 125875
Cell membrane-coated nanoparticles for neurodegenerative disorders management
- 20 June 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 681, 125875
Cell membrane-coated nanoparticles for neurodegenerative disorders management
- 21 September 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 280 (Pt 1) , 135674
Corrigendum to “Sprayed in-situ synthesis of polyvinyl alcohol/chitosan loaded silver nanocomposite hydrogel for improved antibacterial effects” [Int. J. Biol. Macromol. 145 (2020) 950–964]
- 21 September 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 280 (Pt 1) , 135674
Corrigendum to “Sprayed in-situ synthesis of polyvinyl alcohol/chitosan loaded silver nanocomposite hydrogel for improved antibacterial effects” [Int. J. Biol. Macromol. 145 (2020) 950–964]
- 21 September 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 280 (Pt 1) , 135673
Corrigendum to “Synthesis of physically crosslinked PVA/Chitosan loaded silver nanoparticles hydrogels with tunable mechanical properties and antibacterial effects” [Int. J. Biol. Macromol. 149 (2020)1262–1274]
- 21 September 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 280 (Pt 1) , 135673
Corrigendum to “Synthesis of physically crosslinked PVA/Chitosan loaded silver nanoparticles hydrogels with tunable mechanical properties and antibacterial effects” [Int. J. Biol. Macromol. 149 (2020)1262–1274]
- 14 December 2023
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 12 (2) , 382-412
Recent advances in stimuli-responsive tailored nanogels for cancer therapy; from bench to personalized treatment
To improve the quality of health in a personalized manner, better control over pharmacologically relevant cargo formulation, organ-specific targeted delivery, and on-demand release of therapeutic agents is crucial. Significant work has been put into designing and developing revolutionary nanotherapeutics approaches for the effective monitoring and personalized treatment of disease. Nanogel (NG) has attracted significant interest because of its tremendous potential in cancer therapy and its environmental stimuli responsiveness. NG is considered a next-generation delivery technology due to its benefits like as size tunability, high loading, stimuli responsiveness, prolonged drug release via in situ gelling mechanisms, stability, and its potential to provide personalized therapy from the investigation of human genes and the genes in various types of cancers and its association with a selective anticancer drug. Stimuli-responsive NGs can be used as smart nanomedicines to detect and treat cancer and can be tuned as personalized medicine as well. This comprehensive review article's major objectives include the challenges of NGs' clinical translation for cancer treatment as well as its early preclinical successes and prospects.
- 14 December 2023
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 12 (2) , 382-412
Recent advances in stimuli-responsive tailored nanogels for cancer therapy; from bench to personalized treatment
To improve the quality of health in a personalized manner, better control over pharmacologically relevant cargo formulation, organ-specific targeted delivery, and on-demand release of therapeutic agents is crucial. Significant work has been put into designing and developing revolutionary nanotherapeutics approaches for the effective monitoring and personalized treatment of disease. Nanogel (NG) has attracted significant interest because of its tremendous potential in cancer therapy and its environmental stimuli responsiveness. NG is considered a next-generation delivery technology due to its benefits like as size tunability, high loading, stimuli responsiveness, prolonged drug release via in situ gelling mechanisms, stability, and its potential to provide personalized therapy from the investigation of human genes and the genes in various types of cancers and its association with a selective anticancer drug. Stimuli-responsive NGs can be used as smart nanomedicines to detect and treat cancer and can be tuned as personalized medicine as well. This comprehensive review article's major objectives include the challenges of NGs' clinical translation for cancer treatment as well as its early preclinical successes and prospects.
- Open Access
- 12 August 2023
- Published by Royal Society of Chemistry (RSC)
- p. 1-5
Introduction
One of the most intricate bodily processes is the healing of dermal wounds. Multiple cell types with different roles during the phases of hemostasis, inflammati
- 12 August 2023
- Published by Royal Society of Chemistry (RSC)
- p. 1-5
Open AccessIntroduction
One of the most intricate bodily processes is the healing of dermal wounds. Multiple cell types with different roles during the phases of hemostasis, inflammati
- 14 July 2023
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 25 (7) , 1-32
Microneedles for delivery of anticancer therapeutics: recent trends and technologies
- 14 July 2023
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 25 (7) , 1-32
Microneedles for delivery of anticancer therapeutics: recent trends and technologies
- Open Access
- 9 May 2023
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 32, 822-840
Extracellular vesicle-based biovectors in chronic wound healing: Biogenesis and delivery approaches
- 9 May 2023
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 32, 822-840
Open AccessExtracellular vesicle-based biovectors in chronic wound healing: Biogenesis and delivery approaches